Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.65 |
| ▸ | KDR | P35968 | 9/20 | 0.62 |
| ▸ | EGFR | P00533 | 7/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.62 |
| ▸ | FLT1 | P17948 | 4/20 | 0.62 |
| ▸ | FLT4 | P35916 | 3/20 | 0.62 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.56 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | BACE1 | P56817 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3954618 | 1.00 | ENPP1 (0.65) | ENPP1KDREGFRFGFR1FLT1 | |
| SCHEMBL2190137 | 0.94 | ENPP1 (0.64) | ENPP1KDREGFRFGFR1FLT1 | |
| SCHEMBL2188204 | 0.94 | ENPP1 (0.64) | ENPP1KDREGFRFGFR1FLT1 | |
| SCHEMBL5223934 | 0.93 | ENPP1 (0.60) | ENPP1KDREGFRFGFR1FLT1 | |
| SCHEMBL1401681 | 0.92 | ENPP1 (0.64) | ENPP1KDREGFRFGFR1FLT1 | |
| SCHEMBL30408709 | 0.92 | ENPP1 (0.67) | ENPP1KDREGFRFGFR1FLT1 | |
| SCHEMBL18744742 | 0.92 | ENPP1 (0.67) | ENPP1KDREGFRFGFR1FLT1 | |
| SCHEMBL4178028 | 0.92 | ENPP1 (0.67) | ENPP1KDREGFRFGFR1FLT1 | |
| SCHEMBL4379458 | 0.91 | KDR (0.66) | ENPP1KDREGFRFGFR1FLT1 | |
| Hydrochloric Acid SCHEMBL4373335 | 0.89 | KDR (0.64) | ENPP1KDREGFRFGFR1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514460-B2 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2009-04-07 | — | — | US | disclosed |
| EP-1885719-A1 | 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006066795-A1 | 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135782-A1 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135782-A1 | Benzazole analogues and uses thereof | DCK, SBK3, DAPK3 | ENPP1 1457/4885KDR 1657/4885EGFR 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.